Donald B. Kohn, MD, of the University of California, Los Angeles, discusses hematopoietic stem cell gene therapy for primary immune deficiencies. Up to 89% of patients receiving hematopoietic stem cell gene therapy no longer needed immunoglobulin replacement therapy after 2 years. T and B cells were shown to increase to a therapeutic range following gene therapy.